- Home
- USIO vs OKUR Comparison
USIO vs OKUR Comparison
Compare USIO & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- OKUR
- Stock Information
- Founded
- USIO 1998
- OKUR 2011
- Country
- USIO United States
- OKUR United States
- Employees
- USIO N/A
- OKUR N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- OKUR
- Sector
- USIO Finance
- OKUR
- Exchange
- USIO Nasdaq
- OKUR NYSE
- Market Cap
- USIO 37.1M
- OKUR 34.9M
- IPO Year
- USIO N/A
- OKUR N/A
- Fundamental
- Price
- USIO $1.65
- OKUR $2.40
- Analyst Decision
- USIO Strong Buy
- OKUR Strong Buy
- Analyst Count
- USIO 1
- OKUR 4
- Target Price
- USIO $4.00
- OKUR $32.25
- AVG Volume (30 Days)
- USIO 86.9K
- OKUR 71.2K
- Earning Date
- USIO 08-13-2025
- OKUR 08-14-2025
- Dividend Yield
- USIO N/A
- OKUR N/A
- EPS Growth
- USIO N/A
- OKUR N/A
- EPS
- USIO 0.12
- OKUR N/A
- Revenue
- USIO $83,970,504.00
- OKUR N/A
- Revenue This Year
- USIO $16.33
- OKUR N/A
- Revenue Next Year
- USIO $14.56
- OKUR N/A
- P/E Ratio
- USIO $13.54
- OKUR N/A
- Revenue Growth
- USIO 0.46
- OKUR N/A
- 52 Week Low
- USIO $1.24
- OKUR $1.70
- 52 Week High
- USIO $2.92
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- USIO 70.84
- OKUR N/A
- Support Level
- USIO $1.32
- OKUR N/A
- Resistance Level
- USIO $1.69
- OKUR N/A
- Average True Range (ATR)
- USIO 0.08
- OKUR 0.00
- MACD
- USIO 0.03
- OKUR 0.00
- Stochastic Oscillator
- USIO 81.08
- OKUR 0.00
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.